Takayuki Yoshino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2628780/publications.pdf

Version: 2024-02-01

157 papers	16,894 citations	66343 42 h-index	16183 124 g-index
161 all docs	161 docs citations	161 times ranked	14044 citing authors

#	Article	IF	Citations
1	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	13.7	2,276
2	Pembrolizumab in Microsatellite-Instabilityâ€“High Advanced Colorectal Cancer. New England Journal of Medicine, 2020, 383, 2207-2218.	27.0	1,513
3	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2018, 23, 1-34.	2.2	1,187
4	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 1-42.	2.2	1,123
5	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 1909-1919.	27.0	1,027
6	Encorafenib, Binimetinib, and Cetuximab in BRAF V600Eâ€“Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	27.0	918
7	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncology, The, 2015, 16, 499-508.	10.7	753
8	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 2018, 378, 1177-1188.	27.0	699
9	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2012, 17, 1-29.	2.2	658
10	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instabilityâ€“High/Mismatch Repairâ€“Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical Oncology, 2020, 38, 11-19.	1.6	623
11	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. International Journal of Clinical Oncology, 2015, 20, 207-239.	2.2	548
12	Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discovery, 2018, 8, 428-443.	9.4	448
13	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	10.7	286
14	TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2012, 13, 993-1001.	10.7	267
15	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	1.6	254
16	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	10.7	234
17	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature Medicine, 2020, 26, 1859-1864.	30.7	209
18	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clinical Cancer Research, 2019, 25, 7035-7045.	7.0	152

#	Article	IF	Citations
19	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Lancet Oncology, The, 2020, 21, 1620-1629.	10.7	152
20	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer, 2019, 22, 793-802.	5.3	124
21	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 263-270.	8.1	121
22	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncology, The, 2017, 18, 1172-1181.	10.7	111
23	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nature Medicine, 2021, 27, 1899-1903.	30.7	110
24	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6Âmonths) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports, 2013, 9, 261-269.	0.5	94
25	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investigational New Drugs, 2015, 33, 740-750.	2.6	94
26	A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer, 2015, 15, 258.	2.6	93
27	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology, 2021, 39, 642-651.	1.6	84
28	Response to Anti-EGFR Therapy in Patients with BRAF non-V600â€“Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 7089-7097.	7.0	79
29	Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer. JAMA Oncology, 2019, 5, 1574.	7.1	74
30	CIRCULATEâ€Japan: Circulating tumor DNAâ€“guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science, 2021, 112, 2915-2920.	3.9	74
31	Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial. Japanese Journal of Clinical Oncology, 2013, 43, 524-531.	1.3	67
32	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 982-986.	6.4	64
33	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. Journal of Clinical Oncology, 2021, 39, 631-641.	1.6	63
34	12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. Journal of Clinical Oncology, 2016, 34, 2906-2913.	1.6	62
35	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. Clinical Cancer Research, 2022, 28, 1136-1146.	7.0	62
36	Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews, 2020, 86, 101993.	7.7	61

#	Article	IF	Citations
37	A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. Clinical Cancer Research, 2021, 27, 3714-3724.	7.0	61
38	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer, 2016, 16, 467.	2.6	57
39	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 198-205.	2.3	57
40	Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. EBioMedicine, 2015, 2, 317-323.	6.1	54
41	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clinical Colorectal Cancer, 2019, 18, e117-e129.	2.3	53
42	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. British Journal of Cancer, 2017, 117, 1450-1458.	6.4	52
43	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq1 1 0.784314 rgBT /Ove	2.2	49
44	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epsteinâ€“Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer, 2019, 22, 69-76.	5.3	45
45	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. Journal of Clinical Oncology, 2021, 39, 4009-4019.	1.6	45
46	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894.	7.0	44
47	Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit. BMC Cancer, 2013, 13, 405.	2.6	42
48	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. Oncologist, 2018, 23, 1310-1318.	3.7	40
49	KRAS Mutational Status in Japanese Patients with Colorectal Cancer: Results from a Nationwide, Multicenter, Cross-sectional Study. Japanese Journal of Clinical Oncology, 2013, 43, 706-712.	1.3	39
50	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clinical Cancer Research, 2021, 27, 2515-2522.	7.0	39
51	Clinical practice guidance for nextâ€generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1 1 0.784314 rgBT /O	3.9	38
52	Japanese Society of Medical Oncology Clinical Guidelines: <scp>RAS</scp> (<scp>KRAS</scp>/<scp>NRAS</scp>) mutation testing in colorectal cancer patients. Cancer Science, 2015, 106, 324-327.	3.9	37
53	Utility of the quasiâ€monomorphic variation range in unresectable metastatic colorectal cancer patients. Cancer Science, 2018, 109, 3411-3415.	3.9	35
54	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2022, 8, 760.	7.1	35

#	Article	IF	Citations
55	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treatment Reviews, 2021, 98, 102218.	7.7	33
56	Impact of Circulating Tumor DNAâ€“Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181.	3.0	33
57	Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a secondâ€line treatment for Japanese patients with metastatic colorectal cancer. Cancer Science, 2019, 110, 1032-1043.	3.9	30
58	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Antiâ€“PD-1 Therapy. Clinical Cancer Research, 2022, 28, 2110-2117.	7.0	30
59	International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. JCO Precision Oncology, 2020, 4, 6-19.	3.0	29
60	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100535.	3.0	29
61	Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Investigational New Drugs, 2015, 33, 1068-1077.	2.6	28
62	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene, 2018, 37, 1775-1787.	5.9	28
63	Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. Oncologist, 2019, 24, e450-e457.	3.7	28
64	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist, 2020, 25, e1855-e1863.	3.7	28
65	Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. Clinical Cancer Research, 2021, 27, 5619-5627.	7.0	27
66	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2013, 31, 910-917.	2.6	26
67	Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Cancer Chemotherapy and Pharmacology, 2015, 76, 75-84.	2.3	26
68	Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer, 2019, 19, 1253.	2.6	26
69	The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. Oncologist, 2021, 26, 845-853.	3.7	26
70	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. European Journal of Cancer, 2017, 78, 61-69.	2.8	25
71	TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study. Clinical Colorectal Cancer, 2016, 15, e205-e211.	2.3	24
72	Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 855-862.	2.3	24

#	Article	IF	Citations
73	The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. International Journal of Clinical Oncology, 2021, 26, 443-449.	2.2	24
74	SCRUMâ€Japan GIâ€SCREEN and MONSTARâ€SCREEN: Path to the realization of biomarkerâ€guided precision oncology in advanced solid tumors. Cancer Science, 2021, 112, 4425-4432.	3.9	24
75	Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open, 2018, 3, e000354.	4.5	23
76	Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases. Annals of Surgical Oncology, 2021, 28, 4744-4755.	1.5	23
77	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open, 2017, 2, e000261.	4.5	22
78	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 113-120.e1.	2.3	22
79	Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open, 2020, 5, e000775.	4.5	22
80	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncology, 2022, 18, 2351-2360.	2.4	22
81	Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. Neoplasia, 2018, 20, 1219-1226.	5.3	21
82	Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. Clinical Colorectal Cancer, 2016, 15, e109-e115.	2.3	20
83	Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. Annals of Surgical Oncology, 2020, 27, 3307-3315.	1.5	20
84	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer, 2020, 23, 893-903.	5.3	20
85	Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. Anticancer Research, 2015, 35, 4003-7.	1.1	20
86	Impact of DNA integrity on the success rate of tissueâ€based nextâ€generation sequencing: Lessons from nationwide cancer genome screening project SCRUMâ€Japan GIâ€SCREEN. Pathology International, 2020, 70, 932-942.	1.3	19
87	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. BMC Cancer, 2021, 21, 674.	2.6	19
88	Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. Japanese Journal of Clinical Oncology, 2012, 42, 1146-1151.	1.3	16
89	Effect of food on the pharmacokinetics of <scp>TAS</scp>â€102 and its efficacy and safety in patients with advanced solid tumors. Cancer Science, 2016, 107, 659-665.	3.9	16
90	JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 1269-1277.	2.3	15

#	Article	IF	Citations
91	BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open, 2020, 5, e000624.	4.5	15
92	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncology, 2021, 17, 3151-3162.	2.4	14
93	Feasibility and Robustness of Amplification Refractory Mutation System (ARMS)-based KRAS Testing Using Clinically Available Formalin-fixed, Paraffin-embedded Samples of Colorectal Cancers. Japanese Journal of Clinical Oncology, 2011, 41, 52-56.	1.3	13
94	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naÃ¯ve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic ColorectalÂCancer. Clinical Colorectal Cancer, 2017, 16, 158-163.	2.3	13
95	Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ESMO Open, 2018, 3, e000411.	4.5	13
96	The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).. Journal of Clinical Oncology, 2018, 36, 4050-4050.	1.6	13
97	Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, e39-e44.	2.3	12
98	Integrated safety summary for trifluridine/tipiracil (TAS-102). Anti-Cancer Drugs, 2018, 29, 89-96.	1.4	12
99	CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, TPS3619-TPS3619.	1.6	12
100	Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. Journal of Clinical Oncology, 2022, 40, 3419-3429.	1.6	12
101	A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2009, 64, 557-564.	2.3	11
102	Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. BMC Cancer, 2015, 15, 718.	2.6	11
103	Exploration of potential prognostic biomarkers in aflibercept plus <scp>FOLFIRI</scp> in Japanese patients with metastatic colorectal cancer. Cancer Science, 2019, 110, 3565-3572.	3.9	11
104	Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602).. Journal of Clinical Oncology, 2021, 39, 3555-3555.	1.6	11
105	The Essentials of Multiomics. Oncologist, 2022, 27, 272-284.	3.7	11
106	Efficacy and Safety of an Irinotecan plus Bolus 5-Fluorouracil and L-Leucovorin Regimen for Metastatic Colorectal Cancer in Japanese Patients: Experience in a Single Institution in Japan. Japanese Journal of Clinical Oncology, 2007, 37, 686-691.	1.3	10
107	5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Management and Research, 2015, 7, 165.	1.9	10
108	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. Clinical Colorectal Cancer, 2018, 17, e719-e732.	2.3	10

#	Article	IF	Citations
109	Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2021, 39, 2541-2541.	1.6	10
110	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2018, 36, 3530-3530.	1.6	10
111	Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. JCO Precision Oncology, 2020, 4, 1407-1413.	3.0	9
112	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. Annals of Gastroenterological Surgery, 2022, 6, 37-45.	2.4	9
113	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	1.6	9
114	Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. Journal of Bioscience and Bioengineering, 2013, 116, 768-773.	2.2	8
115	FMSâ€like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Science, 2021, 112, 314-322.	3.9	8
116	Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer. Japanese Journal of Clinical Oncology, 2021, 51, 700-706.	1.3	8
117	Phase I study of napabucasin in combination with FOLFIRIâ€‰+â€‰bevacizumab in Japanese patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 2017-2024.	2.2	8
118	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO Precision Oncology, 2022, 6, e2100383.	3.0	8
119	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. Clinical Cancer Research, 2022, 28, 3480-3488.	7.0	8
120	HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naÃ¯ve, HER2-amplified metastatic colorectal cancer. ESMO Open, 2019, 4, e000530.	4.5	7
121	Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094237.	3.2	7
122	BRAF V600E potentially determines â€œOncological Resectabilityâ€•for â€œTechnically Resectableâ€• colorectal liver metastases. Cancer Medicine, 2021, 10, 6998-7011.	2.8	7
123	Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. Journal of Clinical Oncology, 2015, 33, 3564-3564.	1.6	7
124	DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer Science, 2022, 113, 1531-1534.	3.9	6
125	Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect. PLoS ONE, 2014, 9, e105160.	2.5	5
126	Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma. BMC Cancer, 2017, 17, 36.	2.6	5

#	Article	IF	Citations
127	International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.. Journal of Clinical Oncology, 2018, 36, 3594-3594.	1.6	5
128	Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. Anticancer Research, 2012, 32, 973-9.	1.1	5
129	A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 547-553.	2.3	4
130	Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 107-116.	2.3	4
131	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. Clinical Colorectal Cancer, 2019, 18, 269-279.e5.	2.3	4
132	Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. Clinical Journal of Gastroenterology, 2021, 14, 1459-1463.	0.8	4
133	Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110091.	3.2	4
134	The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3591-3591.	1.6	4
135	Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer. Clinical Cancer Research, 2022, 28, 2623-2632.	7.0	4
136	ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into â€œPrecision Oncosurgeryâ€•in Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 3316-3317.	1.5	3
137	Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen.. Journal of Clinical Oncology, 2021, 39, 106-106.	1.6	3
138	Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Project.. Journal of Clinical Oncology, 2021, 39, 152-152.	1.6	3
139	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	2.9	3
140	ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. Lancet Oncology, The, 2022, 23, 463-464.	10.7	3
141	Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. International Journal of Clinical Oncology, 2021, 26, 1238-1247.	2.2	2
142	Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 573-573.	1.6	2
143	An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial.. Journal of Clinical Oncology, 2016, 34, 3550-3550.	1.6	2
144	Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. Future Oncology, 2021, 17, 5013-5022.	2.4	2

#	Article	IF	Citations
145	Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database. Current Oncology, 2022, 29, 3433-3448.	2.2	2
146	Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. International Journal of Clinical Oncology, 2022, 27, 1413-1420.	2.2	2
147	Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan. Current Colorectal Cancer Reports, 2016, 12, 289-295.	0.5	1
148	Activity on Nationwide Cancer Genome Screening Project for Metastatic Colorectal Cancer in Japan; SCRUM-Japan GI-SCREEN. Annals of Oncology, 2019, 30, vi46.	1.2	1
149	Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open, 2019, 4, e000590.	4.5	1
150	Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).. Journal of Clinical Oncology, 2014, 32, TPS3655-TPS3655.	1.6	1
151	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. Journal of Clinical Oncology, 2020, 38, 4099-4099.	1.6	1
152	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. Journal of Gastrointestinal Oncology, 2022, 13, 126-136.	1.4	1
153	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. Targeted Oncology, 2022, , 1.	3.6	1
154	NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	1
155	Response to Letter to the Editor, â€˜Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,â€™ by Ibrahim etÂal.. European Journal of Cancer, 2018, 92, 121-122.	2.8	0
156	Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''. British Journal of Cancer, 2018, 118, 1278-1279.	6.4	0
157	ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve â€œPrecision Onco-Surgeryâ€•in Resectable Colorectal Liver Metastases. Annals of Surgical Oncology, 2021, 28, 4756-4757.	1.5	0